Markets Technology

Proximal Ventures Raises $27.5 Million Debut Fund for AI in Drug Development

First-time manager Sahir Raoof, a former SignalFire investor, will write pre-seed and seed cheques of $500,000 to $1.5 million and has already backed seven startups.

Sahir Raoof, founder of Proximal Ventures
Sahir Raoof, founder of Proximal Ventures (file). Photo: Proximal Ventures

Sahir Raoof has raised $27.5 million for Proximal Ventures, his first solo venture fund, to back startups that apply artificial intelligence to the tools, infrastructure and services used in drug development, TechCrunch reported.

Highlights

  • Raoof raised $27.5 million for his first solo venture fund.
  • Proximal will write pre-seed and seed cheques of $500,000 to $1.5 million.
  • The firm has already backed seven startups, including ChronicleBio.
  • Limited partners include SignalFire, Kleiner Perkins and Bertelsmann Healthcare Investments.
  • Amy Abernethy, a former FDA official, is also an investor.

The bet

First-time fund managers are facing one of the toughest fundraising environments in years, TechCrunch said, but that did not stop Raoof, a former SignalFire investor who also held executive roles at two healthcare startups.

Pharmaceutical companies have long outsourced stages of drug development to specialised service providers, from synthesising molecular compounds and manufacturing drugs at scale to analysing clinical trial data. “For a long time, the assumption was that pharma is not a great buyer of software, but a really good buyer of services,” Raoof told TechCrunch.

He argues that AI could automate much of that work, letting startups deliver the same services at lower cost and in less time, and capture a share of pharmaceutical industry spending. He pointed to law and finance as service-heavy industries where AI has already proved valuable, and said he sees similar openings in pharmaceutical services.

Cheques, portfolio and backers

Proximal plans to invest at pre-seed and seed stage, writing cheques from $500,000 to $1.5 million. It has already backed seven startups, including ChronicleBio, which uses AI to analyse biological and medical data on chronic disease and possible treatments. ChronicleBio was co-founded by Fidji Simo, a former OpenAI executive.

Before two years as a principal at SignalFire, Raoof led business development at clinical trial recruitment startup Iterative Health and oversaw partnerships at Flatiron Health, the oncology data company Roche acquired for $1.9 billion in 2018.

Proximal’s limited partners include SignalFire and Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors such as Dimension Capital co-founders Nan Li and Zavain Dar. Amy Abernethy, co-founder of Highlander Health and a former principal deputy commissioner of the US Food and Drug Administration, is also an investor. She first worked with Raoof at Flatiron Health, where she was chief medical officer, and told TechCrunch that his ability to build relationships and spot industry bottlenecks had stayed with her.

“If you’re building a company that’s selling into the life sciences, one of the hardest things to do is starting that initial commercial flywheel,” Raoof said.

Sources

Filed under

Markets Technology

Written by

Tumisang Bogwasi

Tumisang Bogwasi, Founder & CEO of Brimco. 2X Award-Winning Entrepreneur. It all started with a popsicle stand.

More from this writer